Key Decisions and Approvals

The Board of Directors at their meeting held on 13th August 2026 (commenced at 3:30 PM, concluded at 5:20 PM) approved:

1. Quarterly Standalone Financial Results for quarter ended 30th June 2026 along with Limited Review Report

2. Re-appointment of Mr. Rishit Mehta (DIN: 07121224) as Whole-Time Director

3. Re-appointment of Mr. Haresh Mehta (DIN: 01080289) as Chairman & Whole-Time Director

4. Increase in remuneration payable to Mr. Harshit Mehta (DIN: 05144280), Managing Director

5. Notice of 32nd Annual General Meeting

Financial Results Highlights (Quarter Ended 30th June 2026)

Standalone Financials (Amounts in ₹ Lakhs except per share data):

  • Total Income: ₹6,903.36
  • Total Expenses: ₹6,722.97
  • Profit before Tax: ₹333.95
  • Tax Expense: ₹82.16 (Current Tax: ₹71.00, Deferred Tax: ₹11.16)
  • Profit for the period: ₹251.80
  • Other Comprehensive Income (net of tax): ₹0.93
  • Total Comprehensive Income: ₹277
  • Paid-up Equity Share Capital: ₹209.03 (Face value: ₹2 per share)
  • Other Equity: ₹16,506.80
  • Basic EPS: ₹0.30 (not annualized)
  • Diluted EPS: ₹0.30 (not annualized)

Comparative Figures:

  • Q1 FY2026 (Current Quarter): Profit ₹251.80 lakhs
  • Q1 FY2025 (Previous Year): Profit ₹585.66 lakhs
  • Q4 FY2026 (Previous Quarter): Profit ₹151.83 lakhs

Segment-wise Revenue Breakdown:

  • Sales within India: ₹2,633.62 lakhs
  • Sales outside India: ₹4,269.74 lakhs
  • Total Sales: ₹6,903.36 lakhs

Director Reappointment Details

Mr. Rishit Mehta (DIN: 07121224)

  • Reappointed as Whole-Time Director effective 18th September 2026 for 3 years
  • Qualifications: Bachelor of Engineering (Chemical) from University of Mumbai, Master's Degree in Science from Rutgers University
  • Role: Oversees Production (Technical) and Quality Control departments
  • Experience: 10+ years in pharmaceutical industry
  • Relationships: Immediate relative to Mrs. Rita Mehta, Mr. Harshit Mehta and Mr. Haresh Mehta
  • Compliance: Not debarred from holding director office per SEBI orders

Mr. Haresh Mehta (DIN: 01080289)

  • Reappointed as Chairman & Whole-Time Director effective 18th September 2026 for 3 years
  • Qualifications: Bachelor's Degree in Pharmacy from University of Bombay, Diploma in Industrial Management from Xavier Institute of Management
  • Role: Chairman, Whole-Time Director & Chief Financial Officer overseeing Financial and Legal departments
  • Experience: 45+ years in pharmaceutical industry
  • Relationships: Immediate relative to Mrs. Rita Mehta, Mr. Harshit Mehta and Mr. Rishit Mehta
  • Compliance: Not debarred from holding director office per SEBI orders

Auditor Review

  • Limited review conducted by Shah Shroff & Associates (Firm Registration No.: 128920W)
  • Unmodified review report issued on unaudited financial results
  • Review conducted under SRE 2410 standard
  • Financial results prepared in accordance with IND AS 34 and Companies Act 2013 requirements
  • Previous quarter (ended 31st March 2026) reviewed by previous auditor M/s V J Shah & Co

Additional Information

  • Company operates as single pharmaceutical formulation manufacturing segment (IND-AS 108)
  • No subsidiaries/associates/joint ventures as of 30th June 2026
  • Results available on BSE website (www.bseindia.com), NSE website (www.nseindia.com) and company website (www.medicoremedies.com)
  • Board meeting and audit committee meeting both held on 13th August 2026